SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
SANA

Sana Biotechnology, Inc. (NASDAQ:SANA)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$1.59-$0.15 (-8.62%)
 
Market cap
$476M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 4, 2021
Website
Market Cap$476.42M-55.1%
Revenue (ttm)$0
Net Income-$149.27M+36.3%
EPS-$0.52+46.4%
Shares Out299.63M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,452,514
Open$1.70
Previous Close$1.74
Day's Range$1.56 - $1.75
52-Week Range$1.56 - $5.49
Beta2.30
AnalystsBuy
Price Target$8.67(+445.28%)
Earnings DateMar 2, 2027

About SANA

Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.

Address
188 East Blaine Street, Seattle, WA, 98102, US
Market Cap
476 million
Employees
142
Industrial Classification
Biotechnology
Financial Health Score
Fair
From SANA’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-8.62%
5 Days
-20.10%
1 Month
-32.91%
6 Months
-48.21%
1 Year
-55.08%

$SANA stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in SANA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by SANA's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

SANA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

SANA Revenue by Segment

$64.06MTotal
Income (loss) from operations$18.51M28.89%
Research, development, and laboratory$11.82M18.45%
Facility costs$11.55M18.03%
Support functions$6.88M10.74%
Technical operations and manufacturing$6.84M10.68%
Stock-based compensation$5.33M8.31%
Other$2.46M3.84%
Other income, net$676.00K1.06%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New SANA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to SANA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in SANA

VTIVanguard Morningstar Total Stock Market ETF$12.66M
XBIState Street SPDR S&P Biotech ETF$9.74M
IWMiShares Russell 2000 ETF$7.81M
VXFVanguard Extended Market ETF$5.66M
IWOiShares Russell 2000 Growth ETF$2.82M
VTWOVanguard Russell 2000 ETF$2.59M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from SANA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
100% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BBCVirtus Biotech Clinical Trials ETF0.63%
XBIState Street SPDR S&P Biotech ETF0.11%
OPTZOptimize Strategy Index ETF0.10%
FSEGFidelity Enhanced Small Cap Growth ETF0.05%
IBBQInvesco Nasdaq Biotechnology ETF0.04%
VTWGVanguard Russell 2000 Growth ETF0.03%
IBBiShares Biotechnology ETF0.03%
PWSPacer WealthShield ETF0.02%
BIBProShares Ultra Nasdaq Biotechnology0.02%
LABUDirexion Daily S&P Biotech Bull 3X Shares0.02%
VHTVanguard Health Care ETF0.01%
FHLCFidelity MSCI Health Care Index ETF0.00%

Weight is the stock’s share of each fund’s holdings.